Physician profile
Mark B Weinstein
NPI 1447369095
$17,005.26
in general payments reported to CMS, 2019-2025
39 companies · $2,793 in 2025
The $2,793 reported for 2025 was more than what 83% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,983 · 2020: $1,435 · 2021: $1,830 · 2022: $2,470 · 2023: $3,009 · 2024: $3,486 · 2025: $2,793.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,766 · Education: $522.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,766.09 |
| Education | $521.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,386.28 | 2019-2025 | Skyrizi, Rinvoq, Humira |
| Janssen Biotech, INC. | $2,755.20 | 2019-2025 | Tremfya |
| Lilly USA, LLC | $1,069.28 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $1,007.90 | 2019-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $966.94 | 2022-2025 | Sotyktu |
| Amgen INC. | $906.49 | 2019-2025 | Otezla, Otezla |
| Genzyme Corporation | $900.14 | 2019-2025 | |
| Galderma Laboratories, L.P. | $667.09 | 2019-2025 | Nemluvio, Aklief, Epsolay |
| Ucb, INC. | $660.90 | 2019-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $648.58 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $630.56 | 2019-2025 | Siliq, Targretin, Duobrii |
| Sun Pharmaceutical Industries INC. | $533.59 | 2019-2024 | Ilumya, Odomzo, Blu-U |
| Novartis Pharmaceuticals Corporation | $421.20 | 2019-2025 | |
| Leo Pharma INC. | $419.50 | 2019-2025 | Adbry, Anzupgo |
| Genentech USA, INC. | $252.70 | 2019-2024 | Erivedge, Actemra |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Weinstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.